Discussion Paper
Cancer survival in England and the influence of early diagnosis: what can we learn from recent EUROCARE results?

CS Thomson*1 and D Forman2,3
1Cancer Research UK, Statistical Information Team, 61 Lincoln’s Inn Fields, London WC2A 3PX, UK; 2Centre for Epidemiology and Biostatistics, University of Leeds, Beckett Street, Leeds, UK; 3National Cancer Intelligence Network, Queens House, 56 Lincoln’s Inn Fields, London, UK

BACKGROUND: This review of the EUROCARE-4 results attempts to separate out the early and late mortality effects contributing to the widely reported poorer 5-year survival rates for cancer patients in the United Kingdom compared with other European countries for 26 cancer sites.

METHODS: Patients diagnosed with cancer in 1996–1999 in 23 European countries were included in the analyses. Comparison of 1-year, 5-year and 5|1-year (i.e. only including those patients who had survived to 1 year) survival estimates between data for England and the ‘European average’ was undertaken. This analysis was to highlight the relative contribution of early diagnosis, using 1-year survival as a proxy measure, on 5-year survival for the different sites of cancer. Three groups of cancer sites were identified according to whether the survival differences at 1, 5 and 5|1 years were statistically significant.

RESULTS AND CONCLUSIONS: Breast cancer showed significantly poorer 1- and 5-year survival estimates in England, but the 5|1-year survival figure was not significantly different. Thus, successful initiatives around awareness and early detection could eradicate the survival gap. In contrast, the 5|1-year survival estimates remained significantly worse for lung, colorectal and prostate cancers, showing that although early detection could make some difference, late effects such as treatment and management of the patients were also influencing long-term outcome differences between England and Europe.

British Journal of Cancer (2009) 101, S102 – S109. doi:10.1038/sj.bjc.6605399 www.bjcancer.com
© 2009 Cancer Research UK

Keywords: EUROCARE; cancer survival in England; National Awareness and Early Diagnosis Initiative (NAEDI)

It has been widely reported that 5-year survival rates for cancer patients in the United Kingdom have, in general, lagged behind comparator European countries (and the ‘European average’) since the late 1970s (Berrino et al, 1995b, 1999, 2003, 2007). The NHS Cancer Plan (Department of Health, 2000) highlighted this survival ‘gap’ and ‘catching up with Europe’ has been a major driver in formulating national cancer policy.

High-resolution studies of a few specific sites of cancer undertaken within some of the registries included in EUROCARE-2, and in which additional data on stage and diagnostic techniques were available, suggested that later stage at presentation among UK patients was a major factor explaining the poorer survival. These data are, however, now quite old; they relate to cancers diagnosed in the 1980s and have not been updated (Gatta et al, 2000; Sant et al, 2003, 2007).

The most recently published EUROCARE data, based on new diagnoses between 1995 and 1999, indicate that the survival gap between England and the ‘European average’ had diminished but had not been completely removed (Berrino et al, 2007; Richards, 2007; Verdecchia et al, 2007). As a consequence, the 2007 Cancer Reform Strategy (CRS) maintained an objective of bringing about service improvements to reduce further the difference in survival between England and Europe (Department of Health, 2007).

The CRS set out several initiatives to improve survival including establishment of the National Awareness and Early Diagnosis Initiative (NAEDI). One objective of NAEDI is to review the evidence on links between early diagnosis and survival and evaluate the extent to which international differences in survival are due to differences in delays in patient presentation; in practitioner referrals; in the availability and quality of diagnostic techniques used; and in the management and care of patients once diagnosed.

Use of 1-year survival as a proxy for early/late diagnosis, and hence for stage data, has been advocated in the CRS and comparison of this outcome measure across Europe may help benchmark the current disparities. However, the appropriateness of this measure will vary by cancer site and early/late presentation is not the only possible reason for observed differences. For example, for cancers such as oesophageal and pancreatic with a generally poor prognosis, the introduction of chemotherapeutic regimens for advanced disease will have improved 1-year survival rates for patients irrespective of the proportion of early stage tumours in the populations (Rao and Cunningham, 2008; Starling and Cunningham, 2008; Mitry et al, 2008a, b). Also factors, such as differences in underlying comorbidity, will impact on short-term survival but are rarely adjusted for in comparative survival estimates.

Use of 5-year survival data conditional on surviving 1 year (i.e. 1–5 year or 5|1 survival) has been presented in the most recent EUROCARE-4 publications (Sant et al, 2009). Examination of this along side 1-year survival for different cancer sites shows which sites had variation between the countries at 1 year, which was not present at 5 years after those who died within the first year had been excluded from the analyses. To some extent, this enables

*Correspondence: CS Thomson;
E-mail: catherine.thomson@cancer.org.uk
What can we learn from recent EUROCARE results?
CS Thomson and D Forman

separation of the effects of stage distribution, significant comorbidity and either peri-operative (or postoperative treatment-related) mortality, shown generally by the 1-year survival results, from the effects of treatment and patient management on survival, shown by differences in longer-term survival. This assessment is fundamental to the NAEDI objective of trying to identify cancer sites where delays in diagnosis have had the biggest impact on survival and which could be targeted to reduce such delays in the future.

This paper analyses the most recent EUROCARE data for the more common sites of cancer, comparing outcomes in England with the EUROCARE-4 ‘European average’ at 5, 1 and 5|1 years after diagnosis, and also looks at recent trends in 1-year survival data within England. This provides a means of beginning to identify cancer sites for which the poor outcomes in England can be attributed to later stage at diagnosis.

MATERIALS AND METHODS

The EUROCARE project has been running since 1990 (Berrino et al, 1995a). The latest published data cover patients diagnosed between 1996 and 1999 and are based on 2.8 million adults (aged 15–99) who were diagnosed with cancer in 23 European countries (Sant et al, 2009). Data for 26 of the more common sites or site groups of cancer from the EUROCARE-4 study have been presented. The coding classification used in EUROCARE-4 is the third revision of the International Classification of Diseases for Oncology (ICD-O3).

The data presented here from the EUROCARE-4 study are the figures for England and the ‘European average’, which have both been appropriately standardised for cancer survival analyses. This was to take into account any differences in age structures between the countries, and four different standards are chosen depending on the cancer site of choice. The International Cancer Survival Standard (ICSS; Corazziari et al, 2004) was applied to the EUROCARE-4 data, except for prostate cancer (De Angelis et al, 2009; pp 20). This differs from previous EUROCARE studies, which used internally weighted average age structure for Europe for that study. The ICSS gives standard weights, which should make future comparisons easier.

Data from recent analyses within England (Rachet et al, 2009) for 20 cancer sites or site groupings have also been included. The classification used for this study was the tenth revision of the ICD-10, which is not entirely comparable with those coded using ICD-O3. These data were not originally age standardised although equivalent age-standardised rates were made available to us (personal communication, B Rachet, 2009). The age-standardised data were not reported in the original paper because the authors had found that the age distributions of the cancer patients had changed little over the 11 years they examined. However, the weights used in the age standardisation for the recent study in England (Rachet et al, 2009) were different to those used in the EUROCARE-4 publications. Instead of the ICSS weighting system, Rachet et al (2009) used the ‘England Standard’, which was added to the age distributions of cancer patients diagnosed between 1986 and 1990 in England (Coleman et al, 1999; pp 50). This was to maintain comparability with previous survival analyses within England and used a different set of weights for each of the 20 cancer sites.

The ‘European average’ survival rates reported are not strictly true averages across the whole of Europe. This is because only 13 of the 23 countries represented in EUROCARE-4 have national cancer registration and, hence, 100% coverage. The range of coverage for the other countries was from 1.3% of the adult population for Germany to 58% for Belgium. The data included in EUROCARE-4 covered a population of just over 150 million, which represented about 35% of the population of the combined countries taking part in the study, and 30% of the total EU population (excluding Norway, Switzerland and Iceland, which are not in the EU).

The methodology used to derive the ‘European average’ was neither a simple country-specific weighted average based on coverage, nor one based on population, because either of these averages would have been heavily biased. Instead, regional-specific survival estimates were obtained by splitting Europe into five areas and pooling the data available for the regions. This makes the assumption that the survival for the population covered by registration was representative of the unknown survival of the whole region. Weighting was then applied to each of these five regional estimates using the mean population for those countries included in each EUROCARE-4 region.

The method of creating the ‘European average’ led to the United Kingdom and Ireland region making up 14.6% of the ‘European average’. Thus, comparison of the survival estimates for England (or indeed any other country) with the survival estimate for the ‘European average’ is not strictly straightforward, due to the non-independence between them. However, it was assumed that the covariance (a measure of the non-independence) between the England value and the ‘European average’ would not be large enough to greatly affect interpretation of statistical significance, and as such, the difference between the survival rates for England and the ‘European average’ for each of the 5-year, 1-year and 5|1-year estimates was obtained, along with an estimate of its standard error (i.e.). The standard error for the survival difference was calculated by taking the square root of the sum of the squared standard errors obtained for each of the survival estimates for England and the ‘European average’, ignoring the covariance between the two cohorts.

RESULTS

Table 1 shows results for England and the ‘European average’ for 5, 1 and 5|1-year survival results for 26 of the more common sites or site groups of cancer included in the EUROCARE-4 study. Five-year survival was significantly worse in England for 14 of these cancers, including the four major sites, breast, lung, colorectal and prostate, together with cancers of the oesophagus, stomach, liver, pancreas, cervix, ovary, kidney, bladder, thyroid, melanoma, myeloma and malignant melanoma; and not significantly different for the remaining 10 sites.

All of the 14 cancers showing a statistically significant worse outcome in England at 5 years also showed a significantly worse outcome at 1 year. A further five cancers – bone and cartilage, soft tissue, uterus, bladder and non-Hodgkin lymphoma – also showed a significantly worse 1-year survival, but this was not maintained at 5 years. Of the 14 cancers with significantly worse 5-year outcomes, eight also showed a significantly worse 5|1-year survival – lung, colorectal and prostate together with stomach, ovary, kidney and thyroid cancers and NHL, and ALL and leukaemia. The other six cancers had 5|1-year survival that was no longer significantly different from the ‘European average’. This group included breast cancer together with oesophagus, liver, pancreas, cervix and brain cancers.

Table 2 shows the 14 cancers with significantly worse 5-year outcomes ordered by the magnitude of the 5-year ‘survival gap’ between England and the ‘European average’ together with the corresponding survival gap at 1 year and 5|1 years. Kidney cancer showed the largest survival gap, being 12.4% worse than the ‘European average’ at 5 years, while four other sites had gaps that were larger than 5% worse (stomach (8.4%), prostate (6.7%), ovary (6.3%) and thyroid (5.3%)).

Of the sites for which a statistically significant gap was maintained for 5|1-year survival, all except stomach cancer had a reduced gap in
Table 1 Patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, age-standardised % relative survival (5-year, 1-year and 5|1-year)

| Site*                          | % 5-year survival | % 1-year survival | % 5|1-year survival |
|-------------------------------|-------------------|-------------------|-----------------|
|                               | 'European average' | England EC4 1995–1999 | England – 'European Avg*b | 'European average' | England – 'European Avg*b | 'European average' | England – 'European Avg*b |
| Head and neck                 | 39.5              | 44.8              | Sig higher      | 69.1              | 68.5              | Lower | 57.2              | 65.3              | Sig higher |
| Oesophagus                    | 11.1              | 9.9               | Sig lower       | 35.8              | 32.9              | Sig lower | 30.9              | 30.1              | Lower |
| Stomach                       | 24.5              | 16.1              | Sig lower       | 46.3              | 38.0              | Sig lower | 52.9              | 42.4              | Sig lower |
| Colorectal                    | 54.0              | 50.5              | Sig lower       | 75.8              | 72.2              | Sig lower | 71.2              | 70.0              | Sig lower |
| Liver                         | 9.1               | 7.7               | Sig lower       | 30.0              | 23.7              | Sig lower | 30.2              | 32.5              | Higher |
| Gallbladder and biliary tract | 14.4              | 15.6              | Higher          | 35.9              | 37.7              | Higher | 40.1              | 41.2              | Higher |
| Pancreas                      | 5.7               | 4.4               | Sig lower       | 20.9              | 16.2              | Sig lower | 27.1              | 27.0              | Lower |
| Larynx                        | 62.8              | 63.9              | Higher          | 84.7              | 83.7              | Lower | 74.1              | 76.4              | Sig higher |
| Lung                          | 12.0              | 8.4               | Sig lower       | 36.0              | 26.9              | Sig lower | 33.3              | 31.3              | Sig lower |
| Bone and cartilage            | 55.5              | 52.6              | Lower           | 77.0              | 73.2              | Sig lower | 72.0              | 71.9              | Lower |
| Soft tissue                   | 59.5              | 58.0              | Lower           | 80.4              | 78.6              | Sig lower | 73.9              | 73.8              | Lower |
| Melanoma of skin              | 82.6              | 84.6              | Sig higher      | 95.0              | 96.0              | Sig higher | 87.0              | 88.1              | Sig higher |
| Breast*                       | 79.4              | 77.3              | Sig lower       | 93.8              | 91.8              | Sig lower | 84.6              | 84.2              | Lower |
| Cervix uteri                  | 62.6              | 59.1              | Sig lower       | 84.4              | 80.6              | Sig lower | 74.1              | 73.3              | Lower |
| Corpus uteri                  | 76.2              | 75.2              | Lower           | 89.3              | 87.9              | Sig lower | 85.2              | 85.6              | Higher |
| Ovary and uterine adnexa      | 36.5              | 30.2              | Sig lower       | 66.7              | 59.9              | Sig lower | 54.7              | 50.5              | Sig lower |
| Prostate                      | 76.4              | 69.7              | Sig lower       | 92.7              | 90.2              | Sig lower | 82.4              | 77.3              | Sig lower |
| Testis                        | 89.5              | 89.7              | Higher          | 93.3              | 93.7              | Higher | 96.0              | 95.8              | Lower |
| Bladder                       | 72.4              | 72.4              | Lower           | 86.4              | 84.7              | Sig lower | 83.8              | 85.5              | Sig higher |
| Kidney                        | 58.0              | 45.6              | Sig lower       | 73.8              | 62.7              | Sig lower | 78.6              | 72.6              | Sig lower |
| Brain                         | 19.7              | 17.6              | Sig lower       | 42.7              | 37.1              | Sig lower | 46.0              | 47.4              | Higher |
| Thyroid                       | 82.9              | 77.6              | Sig lower       | 87.6              | 83.7              | Sig lower | 94.6              | 92.8              | Sig lower |
| Hodgkin                       | 80.1              | 78.6              | Lower           | 90.4              | 89.7              | Lower | 88.7              | 87.6              | Lower |
| NHL                           | 51.5              | 50.7              | Lower           | 71.8              | 69.4              | Sig lower | 71.8              | 73.1              | Sig higher |
| Multiple myeloma              | 35.1              | 30.6              | Sig lower       | 72.3              | 67.1              | Sig lower | 48.6              | 45.6              | Sig lower |
| All leukaemias                | 42.4              | 42.3              | Lower           | 64.7              | 64.6              | Lower | 65.6              | 65.4              | Lower |

*Site groups classified according to ICD-O3 coding. 'Sig lower' = England had significantly poorer survival than 'European average'; 'Sig higher' = England had significantly better survival than 'European average'. Non-significant differences were labelled as either 'Lower' or 'Higher' based on the point estimates for England compared with 'European average'. *Based on persons.

Table 2 Patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, % difference in relative survival (5-year, 1-year and 5|1-year) for the 14 sites with significantly lower 5-year survival

| Site*                          | % difference in 5-year survival | % difference in 1-year survival | % difference in 5|1-year survival |
|-------------------------------|---------------------------------|---------------------------------|-----------------|
| Kidney                        | −12.4                           | −11.1                           | −6.0            |
| Stomach                       | −8.4                            | −8.3                            | −10.5           |
| Prostate                      | −6.7                            | −6.3                            | −5.1            |
| Ovary and uterine adnexa      | −6.3                            | −6.8                            | −4.2            |
| Thyroid                       | −5.3                            | −3.9                            | −1.8            |
| Multiple myeloma              | −4.5                            | −5.2                            | −3.0            |
| Lung                          | −3.6                            | −3.6                            | −2.0            |
| Colorectal                    | −3.5                            | −3.8                            | −1.2            |
| Cervix                        | −2.1                            | −2.0                            | −0.8            |
| Breast*                       | −2.1                            | −5.6                            | −0.4            |
| Brain                         | −1.4                            | −6.3                            | 1.4             |
| Liver                         | −1.3                            | −4.7                            | 2.3             |
| Pancreas                      | −1.2                            | −2.9                            | Low             |
| Oesophagus                    | −1.2                            | −2.9                            | Low             |

*Site groups classified according to ICD-O3 coding. 'Sig lower' = England had significantly poorer survival than 'European average'; 'Sig higher' = England had significantly better survival than 'European average'. Non-significant differences were labelled as either 'Lower' or 'Higher' based on the point estimates for England compared with 'European average'. *Based on persons.

comparison with that observed from the conventional 5-year survival analysis. For stomach cancer, survival in England was 10.3% worse than the 'European average' in the 5|1-year analysis (compared with 8.4% for the conventional 5-year outcome). Of the other sites, only kidney (6.0%) and prostate cancer (5.1%) now had gaps of more than 5%.

Figures 1–3 provide graphical comparisons of the differences between England and the 'European average' at 5, 1 and 5|1 years.
Table 3 provides a crude comparison between the EUROCARE-4 data, for both England and the ‘European average’ for patients diagnosed in 1995–1999, with the 1-year survival rates for England between 1996 and 2000 reported in 2009, together with data for 2004–2006 showing changes in 1-year survival rates in England between these two time periods. Due to the different methodologies used, direct comparison between EUROCARE-4 and the more recent England data is not strictly possible but, as expected, for most of the cancers considered, the England results from EUROCARE-4 are fairly similar to the more recent analysis of

![Graph 1](image1.png)

**Figure 1** Five-year survival of patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, age-standardised % relative survival, ‘European average’ and England.

![Graph 2](image2.png)

**Figure 2** One-year survival of patients diagnosed 1995–1999 from the EUROCARE-4 Study followed up to until the end of 2003, age-standardised % relative survival, ‘European average’ and England.
England data for 1996–2000 (the major exception being ovarian cancer for which the EUROCare-4 analysis provides a 1-year survival of 59.9% while the more recent analysis for 1996–2000 estimates 69.1%).

Of the 20 individual cancer sites or site groups considered in Table 3 for England, 17 have shown an improvement in 1-year survival between 1996–2000 and 2004–2006 (the exceptions being cervical cancer (0.1% decrease), Hodgkin disease (1.4% decrease) and leukaemia (2.3% decrease)). These improvements were generally around 1–2% between the two time periods and the major cancers, breast, lung, colon, rectum and prostate all showed survival increases of this magnitude. For testicular cancer, 1-year survival in 1996–2000 was already extremely high (97.8%) and the improvement, by 0.1%, was marginal. The improvements in oesophageal (5.0%), stomach (5.3%) and brain cancer (4.4%) were the most substantial.

Table 3  Age-standardised relative survival (1-year) for patients diagnosed 1995–1999 for England and the 'European average' followed up to the end of 2003 (EUROCARE-4 Study); and patients diagnosed 1996–2000 and 2004–2006 in England (Rachet p. comm) followed up to the end of 2007

| Site a                     | 'European average' 1995–1999 EUROCARE-4 (ICSS) | England 1995–1999 EUROCARE-4 (ICSS) | England 1996–2000 (Rachet) (England Standard) | England 2004–2006 (Rachet) (England Standard) |
|----------------------------|-------------------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Breast                     | 93.8 b                                          | 91.8 b                              | 93.9 c                                        | 95.5 c                                        |
| Lung                       | 36.0                                            | 26.9                                | 27.0 d                                        | 28.9 d                                        |
| Colon                      | 74.2                                            | 69.9                                | 69.5 d                                        | 71.8 d                                        |
| Rectum                     | 78.7                                            | 76.3                                | 76.1 d                                        | 78.1 d                                        |
| Prostate                   | 92.7                                            | 90.2                                | 91.5                                          | 93.3                                          |
| Oesophagus                 | 35.8                                            | 32.9                                | 32.8 d                                        | 37.8 d                                        |
| Stomach                    | 46.3                                            | 38.0                                | 35.8 d                                        | 41.1 d                                        |
| Pancreas                   | 20.9                                            | 16.2                                | 14.7 d                                        | 16.8 d                                        |
| Larynx                     | 84.7                                            | 83.7                                | 83.7 d                                        | 85.8 d                                        |
| Melanoma                   | 95.0                                            | 96.0                                | 95.5 d                                        | 96.6 d                                        |
| Cervix                     | 84.4                                            | 80.6                                | 83.0                                          | 82.9                                          |
| Corpus uteri               | 89.5                                            | 87.9                                | 88.3                                          | 90.1                                          |
| Ovary and uterine adnexa   | 66.7                                            | 59.9                                | 69.1                                          | 71.3                                          |

aSite groups classified according to ICD-O3 coding for EUROCare-4 but using ICD-10 coding for the England analyses by Rachet et al, 2009. bBased on persons. cBased on females only. dEstimates taken as simple averages of the male and female estimates. eBased on males only. ICSS = The International Cancer Survival Standard; ICD-O3 = International Classification of Diseases for Oncology.

Figure 3  1-year survival of patients diagnosed 1995–1999 from the EUROCare-4 Study followed up to until the end of 2003, age-standardised % relative survival, 'European average' and England.
DISCUSSION

Until recently, the only evidence enabling an understanding of the reasons for the relatively poor 5-year survival outcomes in the United Kingdom compared with elsewhere in Europe was the EUROCHECK high-resolution studies (Gatta et al., 2000; Sant et al., 2003, 2007). While these indicated later stage at diagnosis as being an important explanation for part of the difference, the studies only covered a few sites of cancer and were based on relatively small numbers of patients diagnosed during the early 1980s. The samples of UK patients included in these were not necessarily representative of either their regions of residence, or the country as a whole. Relevance to the current situation is, therefore, questionable.

The present review of the EUROCHECK-4 results cannot provide an exhaustive evaluation of the relative contribution of stage at diagnosis to 5-year survival on a site-by-site basis but the analysis of 5, 1 and 5|1-year survival helps provide some overall perspective.

Of the cancer sites considered, one important group is those cancers for which survival in England was significantly worse than the ‘European average’ at 5 years, but separating this into outcomes after 1 year and between 1 and 5 years (i.e. having survived for 1 year) indicated a statistically significant detriment associated only with the former, but not the latter. This implies that, for these cancers, it is low survival in the first year after diagnosis, which gives rise exclusively to the relatively poor overall outcome. The major site falling into this category was breast cancer, but others in this group were cancers of the oesophagus, liver, pancreas, cervix and brain. It is noteworthy that this group includes both breast and cervical cancers for which the benefit of population-based screening has long been established. Both of these cancers are associated with a generally good prognosis and the poor comparative survival in England is probably best explained by relatively small subgroups of women diagnosed with late stage disease, and not being detected by screening.

In contrast, the results for oesophageal, pancreatic and liver cancers, all with an extremely poor prognosis, may be explained in part by differences in access to new therapeutic regimens for advanced disease, which may have started use in England later than elsewhere. For example, the major site falling into this category was breast cancer, but others in this group were cancers of the oesophagus, liver, pancreas, cervix and brain. It is noteworthy that this group includes both breast and cervical cancers for which the benefit of population-based screening has long been established. Both of these cancers are associated with a generally good prognosis and the poor comparative survival in England is probably best explained by relatively small subgroups of women diagnosed with late stage disease, and not being detected by screening.

In contrast, the results for oesophageal, pancreatic and liver cancers, all with an extremely poor prognosis, may be explained in part by differences in access to new therapeutic regimens for advanced disease, which may have started use in England later than elsewhere. For example, the major site falling into this category was breast cancer, but others in this group were cancers of the oesophagus, liver, pancreas, cervix and brain. It is noteworthy that this group includes both breast and cervical cancers for which the benefit of population-based screening has long been established. Both of these cancers are associated with a generally good prognosis and the poor comparative survival in England is probably best explained by relatively small subgroups of women diagnosed with late stage disease, and not being detected by screening.

What we can learn from recent EUROCHECK results?

CS Thomson and D Forman

average, although this is not translated into a differential at 5 years. All of these cancers are associated with reasonable survival rates overall and thus might benefit most from efforts towards earlier diagnosis. With bladder cancer, there is also the additional problem that changes in coding schemes defining the classification of invasive tumours and introduced at different times in different countries, may introduce artefactual survival differences.

The final group of eight cancers are those that had significantly lower survival rates in England at 5 years, which were also evident at both 1 year and 5|1 years. This group included the three common cancers of the lung, colorectum and prostate, as well as cancers of the kidney, thyroid, ovary and stomach and multiple myeloma. The results for these cancers suggest that improving the earlier diagnosis of these cancers would not have eradicated all of the variation observed in 5-year survival between England and Europe. There may also have been differences in the treatment given or the management of services that affected the longer-term outcome. However, the survival gap for all of these sites, except stomach, was smaller between 1–5 years than it was between diagnosis and 5 years (Table 2) indicating a role for earlier diagnosis. In addition, all of these cancers (except thyroid that was not analysed by Rachet et al, 2009) have shown recent improvements in 1-year survival in the England data (Table 3). Prostate cancer survival results are particularly difficult to interpret given the unknown impact of differing intensity of PSA testing in different countries leading to overdiagnosis of non-fatal disease. Coding changes for the classification of invasive behaviour for ovarian cancer make comparisons over time problematic and are most apparent when using the different coding classifications ICD-O3 and ICD-10, as in Table 3.

This analysis dissects the EUROCHECK-4 results to discriminate, among those cancers for which 5-year survival in England seemed to be lagging behind Europe, those for which the explanation seems to be largely due to effects within the year after diagnosis (group one, not showing detrimental 5|1-year outcomes) and those for which the explanation is related to short- and longer-term effects (group three, showing detrimental 1 and 5|1-year outcomes). There is also a group of cancers for which 5-year survival in England was not statistically different from the ‘European average’, but for which there was a detrimental effect at 1 year (group two). It should also be noted that, for 10 of the cancer sites listed in Table 3, there was no statistical difference between the England outcomes and the ‘European average’ at 5 years, and for only two cancers (head and neck and malignant melanoma), England had significantly better survival than Europe.

Efforts and interventions directed towards increased cancer awareness and earlier detection, if successful, are likely to benefit all forms of cancer. Relative improvements to 1-year survival in England are likely to benefit those cancers in groups one and two to such an extent that the survival gap with Europe could almost completely be overcome. NACED could make this improvement to most of the cancers in these two groups although, for the poor prognosis sites (oesophageal, stomach and liver), life-extending theraepies for advanced disease would also be needed. NACED also have an important function in the cancers in group three, although the current survival gap between England and Europe for these cancers is not fully explained by short-term survival differences and other factors will thus also have a role.

This study has several limitations. It is acknowledged that the non-independence between the survival estimates for England and the ‘European average’ means that the method of testing differences between the survival estimates, using only the pooled variance to highlight significant differences, is not perfect. It should, however, be sufficient to help identify which sites require further efforts to separate out the early and late mortality effects and where future international benchmarking projects should be considered.
De Angelis et al (2009) describe the data quality and completeness across the EUROCare-4 data sets, presenting indicators of quality known to affect survival analyses. One of these measures is the percentage of registrations made solely on the basis of death certificates (DCOS), which are excluded from the survival calculations thus biasing the results. High DC0 rates are associated with over-inflation of the survival estimates (Berrino et al, 1995a), and the higher DC0 rates in England compared with Europe (6.1% compared with 2.7%) suggest this is a factor which needs consideration and a possible correction could be applied to survival estimates (Silcocks and Thomson, 2009).

The concept of the 'European average' is itself problematic mainly because the EUROCare-4 Study only covers a minority (about 30%) of the EU population. From the variation within the countries with partial coverage, it is likely that the national estimates for some of these countries would change if 100% population coverage were available, thus, in turn, affecting the 'European average'. Another problem with the 'European average' is that it assumes that all the data sets used in its estimation are of equal quality in terms of accuracy and completeness of recording both incident cases and subsequent deaths. Further discussion of this is provided in both Möller et al (2009) and Abdel-Rahman et al (2009).

An alternative to using the 'European average' for comparison with England would be to identify specific populations with which to compare the results from England; these are likely to be with countries where comparable quality of data to those in England was assured. This is the basis of the future proposed international benchmarking studies.

These results also only give a crude assessment of the possible effects of stage, early diagnosis and treatment on outcomes. A better way to examine these effects is to include this information, when it has been collected robustly, directly in the survival analyses. The high-resolution studies, undertaken as part of the earlier EUROCare studies, attempted this but, partly because of resource constraints involved in data collection, are not available for contemporary comparisons.

Another weakness currently faced is that though it is known how survival has improved in England during the past decade, how this compares with improvements made across Europe is not known. It is possible that the gaps are closing but have not been fully eradicated, and without further studies this cannot be determined for certain (Berrino et al, 2007; Richards, 2007; Verdecchia et al, 2007). This study has focussed on comparing survival within England with the 'European average'. It could be argued that as a rich Western European country, England should be striving to be the equivalent of the 'European best' not just as good as the 'European average'. This was the approach for estimating the numbers of avoidable deaths in the United Kingdom relative to the 'European best' (Abdel-Rahman et al, 2009).

There is, therefore, a need for new international benchmarking studies to assess this. These studies will need to compare registry data within England with other countries with good quality registry data. The data collected will need to contain good staging information, which has been robustly collected to agreed standards, along with information about the diagnostic techniques used, the presence of any significant comorbidity and details of the treatment that was given. Only then may studies provide the real understanding as to how much stage at diagnosis and earlier detection improve cancer survival.

ACKNOWLEDGEMENTS

The authors thank Matt Wickenden for creating and formatting all of the charts for this publication.

Conflict of interest

The authors declare no conflict of interest.

REFERENCES

Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman MP (2009) What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer 101(Suppl 2): S115 – S124

Berrino F, Capocaccia R, Coleman MP, Estève J, Gatta G, Hakulinen T, Micheli A, Sant M, Verdecchia A (eds). (2003) EUROCare-3: the survival of cancer patients diagnosed in Europe during 1990 – 1994. Ann Oncol 14(Suppl 5): 1 – 155

Berrino F, Capocaccia R, Estève J, Gatta G, Hakulinen T, Micheli M, Sant M, Verdecchia A (eds). (1999) Survival of Cancer Patients in Europe: the EUROCare-2 Study (IARC Scientific Publications No. 151). International Agency for Research on Cancer: Lyon

Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Goebergh JW, Santaguiliani M, EUROCare Working Group (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995 – 1999: results of the EUROCare-4 study. Lancet Oncol 8: 773 – 783

Berrino F, Estève J, Coleman MP (1995a) Basic issues in the estimation and comparison of cancer patient survival. In: Survial of Cancer Patients in Europe: the EUROCare Study (IARC Scientific Publications No. 132). Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Estève J (eds), pp 1 – 14. International Agency for Research on Cancer (WHO): Lyon

Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Estève J (1995b) (eds). Survival of Cancer Patients in Europe: the EUROCare Study (IARC Scientific Publications No. 132). International Agency for Research on Cancer: Lyon

Coleman MP, Babb P, Damiecki P, Grosclaude PC, Honjo S, Jones J, Kneler G, Pitard A, Quinn MJ, Sloggett A, De Stavola BL (1999) Cancer Survival Trends in England and Wales 1971 – 1995: Deprivation and NHS Region (Studies on Medical and Population Subjects No. 61). The Stationery Office: London

Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307 – 2316

De Angelis R, Francischi S, Balbi P, Marchesi F, Roazzi P, Belot A, Crocetti E, Pury P, Knijn A, Coleman M, Capocaccia R, EUROCare-4 Working Group (2009) The EUROCare-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 45: 909 – 930

Department of Health (2000) The NHS Cancer Plan. Department of Health: London

Department of Health (2007) Cancer Reform Strategy. Department of Health: London

Gatta G, Capocaccia R, Sant M, Bell CMJ, Goebergh JW, Damhuis RAM, Fautre J, Martinez-Garcia C, Paweega J, Fonz de Leon M, Pottier D, Raverdy N, Williams EMI, Berrino F (2000) Understanding variations in survival for colorectal cancer in Europe: a EUROCare high resolution study. Gut 47: 533 – 538

Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP (2008a) Survival from cancer of the oesophagus in England and Wales up to 2001 – survival analysis. Br J Cancer 99(Suppl 1): S11 – S13

Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP (2008b) Survival from cancer of the pancreas in England and Wales up to 2001 – survival analysis. Br J Cancer 99(Suppl 1): S21 – S23

Möller H, Linklater KM, Robinson D (2009) A visual summary of the EUROCare-4 results: a UK perspective. Br J Cancer 101(Suppl 2): S110 – S114

Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, Ellis L, Walters S, Forman D, Steward J, Coleman MP (2009) Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 10: 351 – 369

Rao S, Cunningham D (2008) Survival from cancer of the oesophagus in England and Wales up to 2001 – clinical commentary. Br J Cancer 99(Suppl 1): S14 – S15
Richards M (2007) EUROCARE-4 studies bring new data on cancer survival. *Lancet Oncol* 8(9): 752–753
Rimassa L, Santoro A (2009) Sorafenib in advanced hepatocellular carcinoma. *Expert Rev Anticancer Ther* 9(6): 739–745
Sant M, Aareleid T, Artiolic ME, Berrino F, Coebergh JW, Colonna M, Forman D, Hedelin J, Rachtan J, Lutz JM, Otter R, Raverdy R, Plesko II, Primic M-Z, Tagliabue G (2007) Ten-year survival and risk of relapse for testicular cancer: A EUROCARE High Resolution Study. *Eur J Cancer* 43: 585–592
Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, Coleman MP, Grosclaude P, Martinez C, Bell J, Youngson J, Berrino F, EUROCARE Working Group (2003) Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. *Int J Cancer* 106: 416–422
Sant M, Allemani C, Santaquiliani M, Kniin A, Marchesi F, Capocaccia R, EUROCARE Working Group (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. *Eur J Cancer* 45: 931–991
Silcocks P, Thomson CS (2009) Correcting population-based survival for DCOs – why a simple method works and when to avoid it. *Eur J Cancer* DOI: 10.1016/j.ejca.2009.06.013 (in press)
Starling N, Cunningham D (2008) Survival from cancer of the pancreas in England and Wales up to 2001 – clinical commentary. *Br J Cancer* 99(Suppl 1): S24–S25
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I, EUROCARE-4 Working Group (2007) Recent cancer survival in Europe: a period analysis 2000–2002 of the EUROCARE-4 data. *Lancet Oncol* 8: 784–796